ADC quantification to classify patients candidate to receive bevacizumab treatment for recurrent glioblastoma

Acta Radiol. 2020 Mar;61(3):404-413. doi: 10.1177/0284185119864842. Epub 2019 Jul 29.
No abstract available

Keywords: Antiangiogenic drug; bevacizumab; diffusion-weighted imaging; glioma; imaging biomarker; magnetic resonance.

MeSH terms

  • Angiogenesis Inhibitors / therapeutic use
  • Bevacizumab / therapeutic use*
  • Brain / diagnostic imaging
  • Brain Neoplasms / diagnostic imaging*
  • Brain Neoplasms / drug therapy
  • Feasibility Studies
  • Glioblastoma / diagnostic imaging*
  • Glioblastoma / drug therapy
  • Humans
  • Magnetic Resonance Imaging / methods
  • Neoplasm Recurrence, Local / diagnostic imaging*
  • Neoplasm Recurrence, Local / drug therapy
  • Patient Selection*
  • Retrospective Studies

Substances

  • Angiogenesis Inhibitors
  • Bevacizumab